Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer—driving down a precarious road in driver-mutated lung cancer

Similar Items

• Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions
  od: Ackermann, Christoph Jakob, i dr.
  Izdano: (2019)
• Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?
  od: Adderley, Helen, i dr.
  Izdano: (2019)
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  od: Ourania Romanidou, i dr.
  Izdano: (2016-05-01)
• Overcoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer
  od: Romanidou, Ourania, i dr.
  Izdano: (2016)
• Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment
  od: Liang, Hongge, i dr.
  Izdano: (2018)